Negative NICE Decision For Avastin® (Bevacizumab) Highlights Challenges Facing UK Access To Medicines

Roche is disappointed that the National Institute for Health and Clinical Excellence (NICE) has published a negative final recommendation (FAD) for the use of Avastin (bevacizumab) in combination with paclitaxel and carboplatin for women with newly-diagnosed advanced ovarian cancer*.(1) This negative decision means that women will continue to rely on their clinicians' successful application to the Cancer Drug Fund (CDF) to access this treatment for advanced ovarian cancer in England...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Ovarian Cancer Source Type: news